Benzinga -
- Cantor Fitzgerald initiated coverage on 15 companies in the Healthcare Services sector. The analysts have a favorable view of payors, acute, outpatient, FemTech, brick-and-mortar alternatives, and opioid abuse treatment centers.
- The analysts have a neutral view on home health and a negative view on inpatient psych. The next few years hold challenges for the payors and acute sectors.
- Cantor initiated coverage on Humana Inc (NYSE: HUM) with an Overweight rating and a price target of $597.
- The analyst views the stock as undervalued, given multiple levers of upside to management's guidance of 14% EPS CAGR 2022-2025, including potential Medicare Advantage (MA) share gains and CenterWell revenue synergies, which could lift core earnings growth above 10%.
- It sees an upside potential to 2023 guidance and 2024 consensus estimates driven by MBR (medical benefit ratio) improvement as a better sales channel mix and comparatively favorable provider negotiations drive better quality in Humana's MA book.
- Also Read: Does Big Pharmacy Managers Fix Prices? Ohio Attorney General Lawsuit Alleges Cigna, Humana Engaged In Price Fixing For Medicines.
- Humana is also well cushioned from potential 2023/2024 provider pricing pressure on network contract renewals.
- Price Action: HUM shares are up 0.27% at $491.65 on the last check Friday.
Mar 2022 | Morgan Stanley | Maintains | Equal-Weight | |
Feb 2022 | SVB Leerink | Maintains | Outperform | |
Jan 2022 | Wells Fargo | Maintains | Overweight |
View the Latest Analyst Ratings
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.